Last $14.07 USD
Change Today -0.08 / -0.57%
Volume 167.1K
As of 8:10 PM 07/25/14 All times are local (Market data is delayed by at least 15 minutes).

angiodynamics inc (ANGO) Snapshot

Open
$14.15
Previous Close
$14.15
Day High
$14.45
Day Low
$14.03
52 Week High
01/10/14 - $19.00
52 Week Low
08/30/13 - $10.84
Market Cap
498.3M
Average Volume 10 Days
147.4K
EPS TTM
$0.22
Shares Outstanding
35.4M
EX-Date
--
P/E TM
63.4x
Dividend
--
Dividend Yield
--
Current Stock Chart for ANGIODYNAMICS INC (ANGO)

angiodynamics inc (ANGO) Related Businessweek News

No Related Businessweek News Found

angiodynamics inc (ANGO) Details

AngioDynamics, Inc. designs, manufactures, and sells medical, surgical, and diagnostic devices. The company offers manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; and venous products, including laser system products used in endovascular laser procedures to treat superficial venous diseases, as well as sclerosing drugs that are used in the treatment of small uncomplicated varicose veins of the lower extremities. It also provides angiographic catheters and guidewires used during peripheral vascular interventional procedures; venous drainage cannula intended for use as a venous drainage cannula during extracorporeal bypass and cardiopulmonary bypass circuit intended for use in procedures requiring extracorporeal circulatory support; and drainage products that drain abscesses and other fluid pockets. In addition, the company offers thrombolytic catheters that are used to deliver thrombolytic agents; renal infusion products to deliver drugs directly to the kidneys in order to prevent and treat acute kidney injuries; micro access sets for minimally-invasive procedures; dialysis catheters that provide short and long-term vascular access for dialysis patients; and peripherally inserted central catheters, implantable ports, and central venous catheters. Further, it provides radiofrequency ablation products, soft tissue surgical ablation products, and microwave ablation products. The company markets and sells its products to interventional radiologists, interventional cardiologists, vascular surgeons, and interventional and surgical oncologists directly in the United States; and directly and through distributors internationally. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

angiodynamics inc (ANGO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $568.6K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $167.2K
Senior Vice President of Global Franchise, On...
Total Annual Compensation: $276.8K
Compensation as of Fiscal Year 2013.

angiodynamics inc (ANGO) Key Developments

AngioDynamics Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended May 31, 2014; Provides Earnings Guidance for the First Quarter and Full Year 2015

AngioDynamics Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended May 31, 2014. The company's net loss was $1.1 million, or $0.03 on a per share basis, compared to net loss of $0.9 million, or $0.02 per share, a year ago. During the company's fourth quarter of fiscal 2014, the state of New York enacted a reform package eliminating the income tax on qualified New York state manufacturers. As a result, anticipated future benefits from net tax assets were eliminated requiring the Company to record a non-cash charge totaling $1.2 million, or $0.03 per share, during the quarter. Adjusted net income was $6.4 million, or $0.18 per share, for the fourth quarter compared to net income of $5.2 million, or $0.15 per share, for the year ago quarter. Fourth quarter EBITDA grew to $9.9 million, or $0.28 per share, compared to $7.9 million, or $0.22 per share, in the year ago comparable period. Adjusted EBITDA was $14.7 million, or $0.41 per share, compared to $13.7 million, or $0.39 per share, in the year ago comparable period. Net sales were $94,065,000 against $90,032,000 a year ago. Operating income was $3,749,000 against $1,230,000 a year ago. Income before income taxes was $2,271,000 against loss of $800,000 a year ago. Adjusted operating income was $11,501,000 against $10,227,000 a year ago. Net cash provided by operating activities was $10,108,000 against $11,369,000 a year ago. Additions to property, plant and equipment was $2,768,000 against $4,412,000 a year ago. Free cash flow was $7.3 million. For the full year, the company's net sales were $354.5 million, a 4% increase compared to the $342 million reported a year ago. The company's net income was $3.1 million, or $0.09 per share, compared to net loss of $0.6 million, or $0.02 per share, reported a year ago. Adjusted net income was $20.6 million, or $0.58 per share, compared to net income of $22.7 million, or $0.64 per share, a year ago. EBITDA was $38.3 million, or $1.08 per share, compared to $32.3 million, or $0.91 per share, a year ago. Adjusted EBITDA was $52.2 million, or $1.47 per share, compared to $57 million, or $1.61 per share, in the year ago period. Net sales were $354,455,000 against $342,026,000 a year ago. Operating income was $13,448,000 against $7,094,000 a year ago. Income before income taxes was $6,380,000 against $643,000 a year ago. Adjusted operating income was $39,437,000 against $43,517,000 a year ago. Net cash provided by operating activities was $25,284,000 against $26,883,000 a year ago. Additions to property, plant and equipment was $11,771,000 against $12,120,000 a year ago. For the full year 2015, the company expects sales of $362 million to $368 million in revenue, reflecting 3-5% growth excluding the impact of the planned wind down of its supply agreement, which the company expects to decline by approximately $4 million as compared to fiscal 2014. Operating leverage in fiscal year 2015 and are guiding to adjusted earnings per share of $0.64-$0.70, representing a 10-21% increase over fiscal 2014. Adjusted EBITDA is expected to improve based on earnings improvement range. The company anticipates revenue to range from $83 million to $86 million in the first quarter of fiscal 2015, a 4% increase at the top end of the range, excluding the wind-down reduction. Adjusted EPS is expected to be in the range of $0.08-$0.12.

AngioDynamics Inc. Receives Novation Innovative Technology Contract Covering BioFlo PICC and BioFlo Port products

AngioDynamics announced receipt of an Innovative Technology Contract for the company's BioFlo PICC and BioFlo Port products from Novation.

AngioDynamics Inc. to Report Q4, 2014 Results on Jul 23, 2014

AngioDynamics Inc. announced that they will report Q4, 2014 results at 5:00 PM, Eastern Standard Time on Jul 23, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANGO:US $14.07 USD -0.08

ANGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Astronics Corp $51.38 USD -2.01
CTS Corp $17.74 USD -0.23
Key Tronic Corp $10.58 USD +0.09
LMI Aerospace Inc $13.25 USD +0.08
Sparton Corp $28.45 USD -0.27
View Industry Companies
 

Industry Analysis

ANGO

Industry Average

Valuation ANGO Industry Range
Price/Earnings 100.0x
Price/Sales 1.4x
Price/Book 0.9x
Price/Cash Flow 25.2x
TEV/Sales 1.0x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANGIODYNAMICS INC, please visit www.angiodynamics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.